Our manuscript entitled “Allosteric inhibition of CRISPR-Cas9 by the anti-CRISPR protein AcrIIA6” is now online and can be accessed via the Molecular Cell website.
Our result suggests that PorE interacts with peptidoglycan and that PorE could anchor the type IX secretion system (T9SS) to the cell wall.
Trinh NTT, Tran HQ, Van Dong Q, Cambillau C, Roussel A, Leone P, (2020). Sci Rep. 10(1):7384. https://doi.org/10.1038/s41598-020-64115-z
We are very happy to welcome Lycia Die Morini in the team. She will be in charge of communication, client consulting, website management and will work as an engineer on the nanobody platform. Welcome Lycia !
First international presentation of our work on the anti-CRISPR protein AcrIIA6 (Cryo-electron microscopy in structural biology: paving the way towards precision biomedicine and biotechnology. A conference in memory of Emilia Chiancone. Roma IT, 10th-11th October 2019)
Radio Broadcast on anti-CRISPR proteins at Radio Canada, Montréal CAN
(http://www.radio-canada.ca/util/postier/suggerer-go.asp?nID=4457104)
Our manuscript entitled “Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity ” is now online and can be accessed via the Cell website.
Strikingly, SARS-CoV and MERS-CoV-infected patients are insensitive to ribavirin, a FDA-approved broad-spectrum antiviral drug. Here, we report an unprecedented RNA correction machinery that was developed by the SARS-CoV. We show that the viral 3’-5’ exonuclease is able to excise either a misincorporated ribonucleotide or ribavirin 5’-monophosphate and to resume RNA synthesis. This proofreading pathway has allowed coronavirus RNA genome size expansion (~ 32 kb in size). This work paves the way for the design of future antiviral strategies using nucleoside analogues.
https://insb.cnrs.fr/fr/cnrsinfo/quand-un-virus-arn-devient-fidele-vers-de-nouvelles-strategies-de-lutte-contre-les
